Home / Stocks / SGRY

Surgery Partners (SGRY, Health Care Facilities) Stock Valuation & Fair Value Trading above fair value

Surgery Partners (SGRY, Health Care Facilities) trades at a blended P/E of 29.1, about 13% below its historical normal valuation, with a forward growth estimate of 16.8% and a PEG of 1.73. Analysts' one-year estimates have been hit 10% of the time. Priced at its historical normal P/E of 33.6 on the same blended earnings, the 2026-09-18 close of $13.25 corresponds to about $15.30 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
29.1
Normal P/E
33.6
PEG
1.73
Fwd growth
16.8%
Div yield
0.0%
RSI (14)
54.0
Neutral
Technical context
  • Price $14.56 at the 2026-09-23 close, 4.1% above the 20-day average ($13.98) and 1.4% below the 50-day ($14.77).
  • RSI (14) at 54.0.
  • 52-week range $11.49 to $22.94: the price is 36.5% below the high and 26.7% above the low.

The Street vs SeerForecast

Wall Street's mean price target for SGRY is $18.82 across 11 analysts, 29.2% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from fairly valued (2026-08-07) to trading above fair value (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 33.2 to 29.1 between 2026-08-07 and 2026-09-21, against a normal P/E of 33.6, with 1 rating change over 16 recorded weeks.2026-08-07: P/E 33.2, Fairly valued (recalculated)2026-08-10: P/E 34.6, Fairly valued2026-08-14: P/E 34.6, Fairly valued (recalculated)2026-08-17: P/E 32.8, Fairly valued2026-08-21: P/E 32.8, Fairly valued (recalculated)2026-08-24: P/E 31.8, Fairly valued2026-08-27: P/E 31.8, Fairly valued (recalculated)2026-08-28: P/E 31.8, Fairly valued (recalculated)2026-08-30: P/E 31.8, Fairly valued (recalculated)2026-08-31: P/E 30.0, Fairly valued2026-09-05: P/E 30.0, Fairly valued (recalculated)2026-09-07: P/E 31.2, Fairly valued2026-09-12: P/E 31.2, Fairly valued (recalculated)2026-09-14: P/E 31.5, Fairly valued2026-09-19: P/E 31.5, Fairly valued (recalculated)2026-09-21: P/E 29.1, Trading above fair value30.032.034.0Aug 7Aug 18Aug 29Sep 10Sep 21Normal P/E 33.6
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 33.2-1%Fairly valued
2026-08-10P/E 34.6+3%Fairly valued
2026-09-21P/E 29.1-13%Trading above fair value ← now

Frequently asked questions

Is Surgery Partners stock overvalued?

At a blended P/E of 29.1 versus its historical normal P/E of 33.6, Surgery Partners trades about 13% below its typical valuation, with a PEG of 1.73 on 16.8% forward growth. tickerseer currently rates it trading above fair value.

What is Surgery Partners's fair value and PEG?

Surgery Partners trades at a blended P/E of 29.1 against a historical normal P/E of 33.6, a PEG of 1.73, and a forward growth estimate of 16.8%. Priced at its historical normal P/E of 33.6 on the same blended earnings, the 2026-09-18 close of $13.25 corresponds to about $15.30 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Surgery Partners changed?

tickerseer's rating moved from fairly valued (2026-08-07) to trading above fair value (2026-09-21).

What is the analyst price target for Surgery Partners?

The mean Wall Street price target for Surgery Partners is $18.82 across 11 analysts, 29.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Facilities. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SGRY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.